Matrix Metalloproteinase 1, 3, and 9 Polymorphisms and Esophageal Squamous Cell Carcinoma Risk

Xuan Guan* (1 School of Basic Medical Sciences, Chengdu Medical College, Chengdu, Sichuan, China), Xiang Wang* (2 Department of Forensic Biology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan, China), Hao Luo (3 Primary Care Center, Sichuan Provincial People’s Hospital, Chengdu, Sichuan, China), Jing Wu (2 Department of Forensic Biology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan, China), Xiao Zhang (1 School of Basic Medical Sciences, Chengdu Medical College, Chengdu, Sichuan, China), Jin Wu (2 Department of Forensic Biology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan, China)

* These authors contributed equally to this work

Corresponding Author: Jin Wu, e-mail: wujin20128@163.com

Source of support: This work was supported by grants from the China Medical Board in New York, the Application Foundation of Sichuan Province (no. 03JY029-089-2) and the Emphatic Programme of Sichuan Province (no. 2006Z09-007-4), China

Background: Matrix metalloproteinases (MMPs) are multifunctional zinc-dependent proteinases that play a fundamental role in the pathogenesis of tumors. We have analyzed the association between 3 single-nucleotide polymorphisms (SNPs; MMP1 -1607 1G/2G, MMP3 -1612 5A/6A, and MMP9 -1562 C/T) and the risk of esophageal squamous cell carcinoma (ESCC).

Material/Methods: We investigated these 3 SNPs in 132 patients and 132 controls using polymerase chain reaction-restriction fragment length polymorphism methods. The MMP1 and MMP3 genes are located on the same chromosome. Haplotype analysis was performed to study the combined effect of the linked MMP polymorphisms on ESCC risk.

Results: The MMP1 and MMP9 promoter polymorphisms were not associated with ESCC risk, while the MMP3 -1612 5A/6A polymorphism was significantly associated with susceptibility to ESCC. Patients carrying the 5A allele had a significantly higher risk for developing ESCC compared with individuals carrying the 6A allele (OR=1.93; 95% CI 1.34–2.77; p<0.01). The 2G-5A and 1G-5A haplotypes were associated with a significantly increased risk of ESCC as compared with the 2G-6A haplotype (OR=2.04, 95% CI 1.37–3.04 and OR=3.65, 95% CI 1.26–10.55, respectively).

Conclusions: These findings implicate this MMP3 polymorphism as a contributor to ESCC susceptibility.

MeSH Keywords: Esophageal Neoplasms • Genetic Association Studies • Matrix Metalloproteinase 1

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/892413
Background

Esophageal cancer is among the 10 most common cancers worldwide [1]. Given its anatomical location, esophageal neoplasia is associated with considerable morbidity, and typical symptoms include progressive dysphagia and weight loss. The 2 major pathological types of esophageal cancer are esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) [2].

China appears to have higher incidence of esophageal cancer than Western nations [3,4]. While the incidence of EAC in Western populations has recently risen and ESCC incidence has fallen [5], ESCC remains the major esophageal malignancy in China. Alcohol consumption and tobacco smoking represent the most significant risk factors for the development of esophageal cancer [6]. However, not all exposed individuals will develop neoplastic disease, suggesting that genetic factors may play key roles in esophageal cancer. Currently, single-nucleotide polymorphisms (SNPs) present in several genes have emerged as significant determinants of disease susceptibility.

Matrix metalloproteinases (MMPs) are a family of at least 20 proteolytic enzymes that play essential roles in cleaving extra cellular matrix (ECM) components. MMPs are classified into 6 subgroups (collagenases, stromelysins, gelatinases, matrilysins membrane-type MMPs, and others), on the basis of their structure and substrate specificity. MMP1, MMP3, and MMP9, represent different groups of MMPs: the collagenases, stromelysins, and gelatinases, respectively [7]. Overexpression of MMP1, MMP3, or MMP9 is closely related to the pathogenesis of tissue-destructive processes in a range of diseases, including ESCC [8–10].

Three polymorphisms have been identified at nucleotides -1607 1G/2G, -1612 5A/6A, and -1562 C/T in the promoter regions of the MMP1, MMP3, and MMP9 genes, respectively, and these have been demonstrated to have functional effects on promoter activity and subsequent gene expression [11–13]. Multiple studies concerning the association of these polymorphisms with susceptibility to various malignancies have been conducted [14–17], but their findings are inconsistent. Until now, only a few [18,19] reports concerning the involvement of these 3 polymorphisms in ESCC have been published. Therefore, the aim of this current study was to ascertain whether SNPs in the promoters of the MMP1, MMP3, and MMP9 genes are associated with the risk of developing ESCC in a Chinese population.

Material and Methods

Subjects

A total of 264 subjects were included in this study. Details of the case and control population have been described previously [20]. Briefly, this study recruited 132 patients with ESCC and 132 healthy controls. All subjects were unrelated ethnic Han Chinese. Patients were consecutively recruited from January 2005 to September 2007 at the People’s Hospital of Suining, Sichuan, China. Diagnosis of ESCC was confirmed by histopathological examination. The ESCC patient group included 74 males and 58 females, with a mean age at diagnosis of 60 years. There were no significant differences in age, sex distribution, or cigarette smoking status between the case group and control group, suggesting that the matching of participants was adequate. The study was approved by the Ethics Committee of the Sichuan Cancer Institute. Written informed consent was obtained from all participants. All participants completed a questionnaire concerning their personal history and smoking history.

Genotyping

Genomic DNA used for the experiment was extracted from peripheral blood by proteinase K digestion and phenol/chloroform extraction. Polymorphism presence was determined using a polymerase chain reaction-restriction fragment length polymorphism method. PCR reactions were carried out in a total volume of 25 μL containing 30–40 ng of genomic DNA, 3.3 μL of sense and 1.6 μL of non-sense oligonucleotide primers and 250 μM of each dNTP, 2.0 μL of Taq DNA polymerase (Promega, Madison, WI) and 2.5% dimethyl sulfoxide (DMSO).

Table 1. Primer sequences and reaction conditions for MMP polymorphism detection.

| Gene polymorphism | Primer sequence | Annealing temperature | Restriction enzyme | Product size (bp) |
|-------------------|-----------------|-----------------------|--------------------|------------------|
| MMP1 -1607 1G/2G | F: TGGCTTTGAAAACATAGCTATGTTCA G: TCTTGGATTGATTTGAGATAAGTCATAGC | 51°C | Alul | 2G: 269 |
| MMP3 -1612 5A/6A | F: GGTCCTCCATCCTTTGATGGGGGGAAGA G: TCTTCGGAATGGCAGCACTGACC | 65°C | TthIII | 6A: 130 |
| MMP9 -1562 C/T | F: ATGGCTCATCCCGCGTAATC G: TGGCGACATCCAGCGGATTC | 62°C | SphI | 5A: 96 +34 |

Indexed in: [Current Contents/Clinical Medicine] [ISI Expanded] [ISI Alerting System] [EMBASE/Excerpta Medica] [Index Copernicus]
Table 2. Characteristics of study subjects.

| Group          | Controls n=132 (%) | ESCC patients n=132 (%) | Significance |
|----------------|--------------------|-------------------------|--------------|
| Age (years)    | 60.4 ±8.42         | 60.0 ±9.33              | .55*         |
| Gender         |                    |                         |              |
| Male           | 83 (62.88)         | 74 (56.06)              | .26**        |
| Female         | 49 (37.12)         | 58 (43.94)              |              |
| Smoking        |                    |                         |              |
| Smoker         | 56 (42.42)         | 63 (47.73)              | .39**        |
| Non-smoker     | 76 (57.58)         | 69 (52.27)              |              |

*p value for t-test; ** Value for χ²-test.

1 mol/l dNTP, 2.5 μL of 10 × PCR Buffer, 25 mM MgCl₂, 0.3 μL each 10 μM primer, and 0.3 μL 2.5 U/μL Taq polymerase, with the remaining volume DDH₂O. The details of primer sequences, annealing temperature, and restriction enzymes used are shown in Table 1. PCR products were digested overnight at 37°C with 0.5 U of the indicated restriction enzyme. Digestion products were then analyzed directly by vertical non-denaturing polyacrylamide gel electrophoresis and visualized by silver staining. To confirm the genotyping results, PCR-amplified DNA samples were examined with DNA sequencing. No differences were found in either quality controls and the results were 100% concordant.

Statistical analysis

Genotype and allele frequencies were compared between patients and controls using the χ² and Fisher’s exact tests as appropriate. Tests of Hardy-Weinberg equilibrium were calculated with an observed genotype frequencies of fit χ² test with 1 degree of freedom. The odds ratio (OR) and 95% confidence interval (CI) were calculated to assess the relative risk conferred by a particular allele and genotype. Statistical significance was set at p<0.05. These analyses were performed using SPSS 15.0 software. Simultaneously, the MMP1 −1607 1G/2G and MMP3 −1612 5A/6A haplotype frequencies and linkage disequilibrium coefficient were estimated using the PHASE 2.0 program [21].

Results

Characteristics of the study subjects

The characteristics of the 132 ESCC patients and 132 control subjects included in this study are summarized in Table 2. No statistical differences in age and sex distribution were identified between ESCC patients and control individuals, suggesting that frequency-matching based on these variables was adequate. No family history of ESCC was reported among controls or cases.

The genotype and allele frequencies of MMPs

The genotype distributions in the total sample were present in Hardy-Weinberg equilibrium. The genotype and allele frequencies of the 3 SNPs (MMP1 −1607 1G/2G, MMP3 −1612 5A/6A, and MMP9 −1562 C/T) are summarized in Table 3. For MMP3 −1612 5A/6A, there was a significant difference in the genotype and allele frequencies of this polymorphism between ESCC and control subjects. The 6A5A and 5A5A genotypes were associated with a significantly higher risk of ESCC as compared with the 6A6A genotype (OR=1.92; 95% CI 1.14–3.23; p<0.05 and OR=5.42; 95% CI 2.01–14.63; p<0.01, respectively). Using the 6A allele as a reference, a significant correlation was detected between the presence of the 5A allele and a risk of developing ESCC (OR=1.93; 95% CI 1.34–2.77; p<0.01). However, genotype and allele frequencies of the MMP1 −1607 1G/2G and MMP9 −1562 C/T polymorphisms in ESCC patients were not significantly different from those in healthy controls (p>0.05). Since the MMP1 and MMP3 genes are located in the same chromosome region (11q22.3), haplotype analysis was calculated and the estimated haplotype frequencies are summarized in Table 4. The results of 2LD analysis revealed that the MMP1 −1607 1G/2G and the MMP3 −1612 5A/6A polymorphisms displayed a linkage disequilibrium (D’=0.51) in healthy subjects. Haplotype analysis indicated that 2G-6A was the most common haplotype in healthy controls (39.6%), followed by the 2G-5A (37.3%), 1G-6A (18.0%), and 1G-5A (5.1%) haplotypes. The 2G-5A and 1G-6A haplotypes were associated with a significantly increased risk of ESCC as compared with the 2G-6A haplotype (OR = 2.04, 95% CI 1.37–3.04 and OR=3.65, 95% CI 1.26–10.55, respectively). Our study demonstrated 86% (MMP1 −1607 1G/2G), 87% (MMP3 −1612 5A/6A), and 88% (MMP9
### Table 3. Genotype and allele frequencies of three SNPs in the MMPs gene between ESCC patients and controls.

| Polymorphisms | Controls n=132 (%) | ESCC patients n=132 (%) | OR (95% CI)       | p     |
|----------------|-------------------|-------------------------|-------------------|-------|
| **MMP1-1607 1G/2G** |                   |                         |                   |       |
| Genotypes      |                   |                         |                   |       |
| 2G2G           | 87 (65.91)        | 81 (61.36)              | 1.00 (Ref)        |       |
| 2G1G           | 40 (30.30)        | 41 (31.06)              | 1.10 (0.65–1.87)  | .72   |
| 1G1G           | 5 (3.9)           | 10 (7.58)               | 2.15 (0.70–6.55)  | .17   |
| Alleles        |                   |                         |                   |       |
| 2G             | 214 (84.47)       | 203 (76.89)             | 1.00 (Ref)        |       |
| 1G             | 50 (15.53)        | 61 (23.11)              | 1.29 (0.85–1.96)  | .24   |
| **MMP3-1612 5A/6A** |                   |                         |                   |       |
| Genotypes      |                   |                         |                   |       |
| 6A6A           | 65 (49.24)        | 40 (30.30)              | 1.00 (Ref)        |       |
| 6A5A           | 61 (46.21)        | 72 (54.55)              | 1.92 (1.14–3.23)  | .01   |
| 5A5A           | 6 (4.55)          | 20 (15.15)              | 5.42 (2.01–14.63) | <.001 |
| Alleles        |                   |                         |                   |       |
| 6A             | 191 (72.35)       | 152 (57.58)             | 1.00 (Ref)        |       |
| 5A             | 73 (27.65)        | 112 (42.42)             | 1.93 (1.34–2.77)  | <.001 |
| **MMP9-1562 C/T** |                   |                         |                   |       |
| Genotypes      |                   |                         |                   |       |
| CC             | 92 (69.70)        | 84 (63.64)              | 1.00 (Ref)        |       |
| CT             | 34 (27.98)        | 38 (28.79)              | 1.22 (0.71–2.12)  | .47   |
| TT             | 6 (4.01)          | 10 (7.58)               | 1.85 (0.64–5.24)  | .26   |
| Alleles        |                   |                         |                   |       |
| C              | 218 (82.58)       | 206 (78.03)             | 1.00 (Ref)        |       |
| T              | 46 (17.42)        | 58 (21.97)              | 1.33 (0.87–2.05)  | .19   |

Ref – reference category.

### Table 4. Haplotype distribution in the patients with ESCC and controls.

| Haplotype | Controls n=264 (%) | ESCC patients n=264 (%) | OR (95% CI)       | p     |
|-----------|--------------------|-------------------------|-------------------|-------|
| 2G-6A     | 146 (55.30)        | 104 (39.6)              | 1.00 (Ref)        |       |
| 2G-5A     | 68 (25.80)         | 99 (37.30)              | 2.04 (1.37–3.04)  | <.01  |
| 1G-6A     | 45 (17.10)         | 48 (18.00)              | 1.50 (0.98–2.42)  | .01   |
| 1G-5A     | 5 (1.90)           | 13 (5.10)               | 3.65 (1.26–10.55) | .01   |
-1562 C/T) power to detect an effect with an odds ratio of 2.2 in cases versus controls under a dominant genetic model.

**Discussion**

Our results appear to be in line with the well-documented functional relevance of the MMP3 -1612 5A/6A SNP. Accordingly, this suggests that MMP3 gene polymorphisms may be useful genetic susceptibility markers for ESCC.

MMPs are a pivotal family of zinc-dependent enzymes that are involved in all stages of cancer progression. MMPs are considered to be particularly important for the invasion and metastasis processes of cancer cells, as these require proteinolysis of the ECM and basement membrane. However, recent studies have reported that MMPs are involved in regulating tumor cell growth, apoptosis, invasion, cell adhesion, metastasis, angiogenesis, cell signaling, and immune surveillance [22,23]. In normal tissues, MMP levels are usually low. Accordingly, overexpression of MMP1, MMP3, or MMP9 may contribute to the pathogenesis of tissue-destructive processes in ESCC. Functional studies indicate that the -1607 1G/2G, -1612 5A/6A, and -1562 C/T polymorphisms affect MMP1, MMP3, and MMP9 promoter activities, respectively.

MMP9, also called gelatinase B and 92-kDa type IV collagenase, is involved in the breakdown of gelatin, collagens and elastin [24]. To our knowledge, a link between the MMP9 -1562 C/T polymorphism and ESCC has not previously been established. Zhang et al. [13] first reported that the MMP9 -1562 C/T polymorphism created a binding site for a transcriptional repressor protein. We therefore suspected that this functional polymorphism could be involved with ESCC pathogenesis. However, we did not find any link between the MMP9 -1562 C/T polymorphism and ESCC in this study.

The MMP1 gene promoter carries a common deletion/insertion polymorphism at position -1607. The 2G allele, as opposed to the 1G allele, is associated with the creation of a new 5’-GGA-3’ core recognition sequence for the Ets family of transcription factors [11]. Our finding was consistent with the findings of a previous report that found no association between the MMP1 polymorphism and ESCC risk.

The MMP1 (human collagenase-1) and MMP3 (human stromelysin-1) genes are located in the same chromosome region (11q22.3). Both are produced by macrophages, stromal fibroblasts, and epithelial cells and MMP3 exhibits proteolytic activity on numerous extracellular matrix proteins [25]. Additionally, MMP3 is capable of activating several other MMPs, including MMP1 and MMP9. Moreover, MMP3 can influence the secretion of some cell-surface molecules, including E-cadherin, and promote tumor formation and progression [26]. The MMP3 gene promoter has a dimorphism at position -1172, where either 5 (5A allele) or 6 (6A allele) adenosine residues are found. Deletion of an adenosine (5A) leads to increased MMP3 transcription compared with the 6A allele in vitro [27]. Therefore, the presence of the MMP3 -1612 5A/6A SNP polymorphism is associated with an increased risk of developing a range of cancers, including colorectal adenoma [28], hepatocellular carcinoma [29], and lung cancer [30]. This study identified a higher frequency of the 5A allele in ESCC patients (OR 1.53; p=0.035) when compared with controls. The frequency of the MMP3 5A allele among control Chinese individuals was 0.276, which was significantly lower than that reported in Austria (0.470) [31], Italy (0.440) [14], Czech Republic (0.483) [32], and Sweden (0.536) [32]. Zhang et al. [33] indicated that the MMP3 5A allele was a significant risk factor for ESCC only in current or ex-smokers, suggesting that the effect of the MMP3 -1612 5A/6A polymorphism on ESCC might be influenced by cigarette smoking. In the current study, we found no evidence to support this.

There are several limitations to our study. Firstly, this was a hospital-based case-control study. Secondly, the subjects were not adjusted in our logistic regression models because of the lack of detailed information about their diet, alcohol consumption, and environmental data. Finally, we selected common SNPs within the same haplotype structure instead of haplotype tagging SNPs, and the selection criteria for the candidate polymorphisms were based on evidence of putative functional change. This strategy may lead to inherited error in the analysis, and further studies with larger samples are needed to explore this further.

In summary, our research provides evidence that the MMP3 -1612 5A/6A polymorphism is a genetic susceptibility factor for the development of ESCC in a Chinese population. Additionally, the 2G-5A and 1G-5A haplotypes are associated with a higher risk of ESCC. Further studies in diverse ethnic populations are needed to verify our results, and an evaluation of gene-environment interactions on the risk of ESCC development would also be of great value.

**Conclusions**

These findings implicate this MMP3 polymorphism as a contributor to ESCC susceptibility.

**Acknowledgments**

We thank Xu Quan Yang for providing samples and clinical information.

**Disclosure statement**

No competing financial interests exist.
References:

1. Parkin DM, Bray F, Ferlay J et al: Global cancer statistics, 2002. Cancer J Clin, 2005; 55: 74–108
2. Klimstra DS: Pathologic prognostic factors in esophageal carcinoma. Semin Oncol, 1994; 21: 425–30
3. Gao YT, McLaughlin JK, Blot WJ et al: Risk factors for esophageal cancer in Shanghai, China. I. Role of cigarette smoking and alcohol drinking. Int J Cancer, 1994; 58: 139–47
4. Yang L, Parkin DM, Li L et al: Time trends in cancer mortality in China: 1987-1999. Int J Cancer, 2003; 106: 771–83
5. Stoner GD, Gupta A: Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis, 2001; 22: 1737–46
6. Lauton G, Milan CH, Faivre J et al: Alcohol, tobacco and esophageal cancer: effects of the duration of consumption, mean intake and current and former consumption. Br J Cancer, 1997; 75: 1389–96
7. Parsons SL, Watson SA, Brown PD et al: Matrix metalloproteinases. Br J Surg, 1997; 84: 160–66
8. Murray GI, Duncan ME, O’Neill P et al: Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol, 1998; 185: 256–61
9. Shima S, Sasaguri Y, Kusukawa J et al: Production of matrix metalloproteinase-2 and matrix metalloproteinase-3 related to malignant behavior of esophageal carcinoma. Cancer, 1992; 70: 2747–53
10. Tanioka Y, Yoshida T, Yasawa T et al: Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer, 2003; 89: 2116–21
11. Fujimoto T, Parry S, Urbanek M et al: A single nucleotide polymorphism in the matrix metalloproteinase-1 (MMP-1) promoter influences amnion cell MMP-1 expression and risk for preterm premature rupture of the fetal membranes. J Biol Chem, 2002; 277: 6296–302
12. Ye S, Watts GF, Mandalia S et al: Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res, 2006; 69: 636–45
13. Zhang B, Ye S, Herrmann SM et al: Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation, 1999; 99: 1788–94
14. Ghilardi G, Biondi ML, Caputo M et al: A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter influences amnion cell MMP-1 expression and risk for preterm premature rupture of the fetal membranes. J Biol Chem, 2002; 277: 6296–302
15. Hinoda Y, Okayama N, Takano N et al: Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer. Int J Cancer, 2002; 102: 526–29
16. Hirata H, Naito K, Yoshitoh S, et al: A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter is associated with conventional renal cell carcinoma. Int J Cancer, 2003; 106: 372–74
17. Sugimoto M, Yoshida S, Kennedy S et al: Matrix metalloproteinase-1 and -9 promoter polymorphisms and endometrial carcinoma risk in a Japanese population. J Soc Gynecol Investig, 2006; 13: 523–29
18. Jin X, Kuang G, Wei LZ et al: No association of the matrix metalloproteinase 1 promoter polymorphism with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in northern China. World J Gastroenterol, 2005; 11: 2385–89
19. Zhang J, Jin X, Fang S et al: The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastasis in esophageal squamous cell carcinoma but not in gastric cardiac adenocarcinoma. Carcinogenesis, 2004; 25: 2519–24
20. Wu J, Zhang L, Luo H et al: Association of matrix metalloproteinases-9 gene polymorphisms with genetic susceptibility to esophageal squamous cell carcinoma. DNA Cell Biol, 2008; 27: 553–57
21. Stephens M, Donnelly P: A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet, 2003; 73: 1162–69
22. Deryugina EI, Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev, 2006; 25: 9–34
23. Egeland M, Wiberg Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer, 2002; 2: 161–74
24. Wilson CL, Matrisian LM: Matrixilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol, 1996; 28: 123–36
25. Tettlow LC, Lees M, Woolley DE: Comparative studies of collagenase and stromelysin-1 expression by rheumatoid synoviocytes in vitro. Virchows Arch, 1995; 425: 569–76
26. Johannson N, Ahonen M, Kähäri VM: Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci, 2000; 57: 5–15
27. Ye S: Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res, 2006; 69: 636–45
28. Ljørke E, Milet I, Carayol J et al: Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma. BMC Cancer, 2006; 6: 270
29. Okamoto K, Ishida C, Ikebuchi Y et al: The genotypes of IL-1 beta and MMP-3 are associated with the prognosis of HCV-related hepatocellular carcinoma. Intern Med, 2010; 49: 887–95
30. Fang S, Jin X, Wang R et al: Polymorphisms in the MMP1 and MMP3 promoters and non-small cell lung carcinoma in North China. Carcinogenesis, 2006; 26: 481–86
31. Krippel P, Langsenlehner U, Renner W et al: The 5A/6A Polymorphism of the Matrix Metalloproteinase 3 Gene Promoter and Breast Cancer. Clin Cancer Res, 2004; 10: 3518–20
32. Lei H, Zaloudik J, Vorechovsky I: Lack of association of the -1171(5A) allele of the MMP3 promoter with breast cancer. Clin Cancer Res, 2002; 8: 48: 798–99
33. Zhang J, Jin X, Fang S et al: The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastasis in esophageal squamous cell carcinoma but not in gastric cardiac adenocarcinoma. Carcinogenesis, 2004; 25: 2519–24